Skip to main content

LUP Student Papers

LUND UNIVERSITY LIBRARIES

Definition of Relevant Product Market in Reference to R&D Poles in Pharmaceutical Sector Mergers

Karus, Kärt LU (2015) JAEM03 20151
Department of Law
Abstract
All competition analysis, including in relation to mergers, begins by defining the relevant market. In sectors where innovation plays a major role, the definition of the relevant market must also take into account the R&D efforts of the merging firms. One field in which R&D poles can be identified early on is the pharmaceutical sector. In March 2015, the European Commission released the public version of the Novartis/GlaxoSmithKline Oncology Business merger decision, which clarified the market definition process of the Commission regarding R&D poles. The aim of this thesis is to answer the question of how to define relevant product markets concerning R&D poles in pharmaceutical sector mergers. The analysis takes into account the aims of... (More)
All competition analysis, including in relation to mergers, begins by defining the relevant market. In sectors where innovation plays a major role, the definition of the relevant market must also take into account the R&D efforts of the merging firms. One field in which R&D poles can be identified early on is the pharmaceutical sector. In March 2015, the European Commission released the public version of the Novartis/GlaxoSmithKline Oncology Business merger decision, which clarified the market definition process of the Commission regarding R&D poles. The aim of this thesis is to answer the question of how to define relevant product markets concerning R&D poles in pharmaceutical sector mergers. The analysis takes into account the aims of European Union Competition Law and the possible dangers which may result from different relevant product market definitions. (Less)
Please use this url to cite or link to this publication:
author
Karus, Kärt LU
supervisor
organization
course
JAEM03 20151
year
type
H2 - Master's Degree (Two Years)
subject
keywords
R&D, relevant product market, innovation markets, pharmaceutical sector, Merger control
language
English
id
7451069
date added to LUP
2015-07-16 15:10:43
date last changed
2015-07-16 15:10:43
@misc{7451069,
  abstract     = {{All competition analysis, including in relation to mergers, begins by defining the relevant market. In sectors where innovation plays a major role, the definition of the relevant market must also take into account the R&D efforts of the merging firms. One field in which R&D poles can be identified early on is the pharmaceutical sector. In March 2015, the European Commission released the public version of the Novartis/GlaxoSmithKline Oncology Business merger decision, which clarified the market definition process of the Commission regarding R&D poles. The aim of this thesis is to answer the question of how to define relevant product markets concerning R&D poles in pharmaceutical sector mergers. The analysis takes into account the aims of European Union Competition Law and the possible dangers which may result from different relevant product market definitions.}},
  author       = {{Karus, Kärt}},
  language     = {{eng}},
  note         = {{Student Paper}},
  title        = {{Definition of Relevant Product Market in Reference to R&D Poles in Pharmaceutical Sector Mergers}},
  year         = {{2015}},
}